Home  >  News
Msc_Apr22 Advertisement
you can get e-magazine links on WhatsApp. Click here
Clinical Trials + Font Resize -

Daiichi Sankyo to present new breast cancer data across DXd ADC portfolio at SABCS21

Monday, December 6, 2021, 17:00 Hrs  [IST]

Daiichi Sankyo Company Limited will present new breast cancer research data across its DXd ADC portfolio at the 2021 San Antonio Breast Cancer Symposium (#SABCS21) to be held on December 7-10, 2021.

Additional analyses from the head-to-head DESTINY-Breast 03 phase 3 trial of Enhertu (trastuzumab deruxtecan) versus trastuzumab emtansine (T-DM1) in patients with previously treated HER2 positive metastatic breast cancer along with updated results from the triple negative breast cancer (TNBC) cohort of the TROPION-PanTumor 01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) will be highlighted in oral presentations. Trials-in-progress from other ongoing breast cancer trials in the DESTINY clinical development programme of Enhertu as well as a collaborative window of opportunity study conducted by SOLTI Breast Cancer Research Group with patritumab deruxtecan (HER3-DXd) in patients with previously untreated early stage breast cancer also will be featured.

“Our goal is to continuously improve the standard of care in patients with breast cancer across different subtypes and treatment settings including neoadjuvant, adjuvant and metastatic disease with our innovative ADC portfolio,” said Ken Takeshita, MD, global head, R&D, Daiichi Sankyo. “We look forward to presenting updatesfrom the DESTINY-Breast03 trial and TROPION-PanTumor01 trial, two important trials that demonstrate the strength and potential of our DXd ADC technology in creating transformative medicines for patients with cancer.”

The DXd ADC portfolio of Daiichi Sankyo consists of six ADCs with five in clinical development across multiple types of cancer. The company’s three lead ADCs include Enhertu, a HER2 directed ADC, datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca; and patritumab deruxtecan (HER3-DXd), a HER3 directed ADC.

Two additional ADCs, DS-7300 (B7-H3) and DS-6000 (CDH6), are being developed through a strategic collaboration with Sarah Cannon Research Institute. Each ADC is designed using Daiichi Sankyo’s proprietary DXd ADC technology to target and deliver chemotherapy inside cancer cells that express a specific cell surface antigen. Each ADC is composed of a monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a tetrapeptide-based cleavable linker.

Enhertu (5.4 mg/kg) (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in US only) is approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens based on the results from the DESTINY-Breast01 trial.

Enhertu (6.4 mg/kg) is approved in Israel, Japan, Singapore and U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial. A Type II Variation is currently under review by the European Medicines Agency (EMA) for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or GEJ adenocarcinoma who have received a prior anti-HER2-based regimen.

Enhertu is approved in the US with Boxed WARNINGS for Interstitial Lung Disease and Embryo-Fetal Toxicity. For more information, please see the accompanying full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Datopotamab deruxtecan, patritumab deruxtecan, DS-7300 and DS-6000 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |